Intelligent Bio Solutions Inc. (INBS)vsStryker Corporation (SYK)
INBS
Intelligent Bio Solutions Inc.
$3.35
+1.82%
HEALTHCARE · Cap: $5.50M
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 701210% more annual revenue ($25.12B vs $3.58M). SYK leads profitability with a 12.9% profit margin vs 0.0%. SYK earns a higher WallStSmart Score of 65/100 (C+).
INBS
Hold40
out of 100
Grade: D
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INBS.
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 47.6% year-over-year
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -1.5% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth. Revenue growth of 47.6% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Profit Margin.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
INBS profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.63 — expect wider price swings.
INBS is growing revenue faster at 47.6% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (65/100 vs 40/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology company committed to revolutionizing healthcare through the development of innovative diagnostic solutions and biomarker-driven technologies, especially in the realm of drug abuse testing and monitoring. Leveraging cutting-edge scientific advancements, the company aims to enhance healthcare outcomes by offering highly accurate and rapid-testing methodologies that facilitate timely clinical decision-making. Positioned strategically at the nexus of technology and healthcare, INBS is well-positioned to capitalize on the growing demand for advanced diagnostic tools in a dynamic market landscape.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?